Atomwise Appoints Steve Worland as CEO to Lead AI-Driven Drug Discovery
Atomwise has appointed Steve Worland, Ph.D., as its new Chief Executive Officer, announced in a press release. Worland, who has over 30 years of experience in the biotechnology and pharmaceutical sectors, will work with Atomwise's management and board to advance the company's AI-driven drug discovery platform, AtomNet.
Worland's extensive background includes leadership roles at eFFECTOR Therapeutics, Anadys Pharmaceuticals, and Pfizer. His scientific contributions have been pivotal in the development of several clinical-stage products. At Atomwise, he aims to leverage his expertise to enhance the company's proprietary pipeline and optimize its AI capabilities for drug discovery.
Additionally, Atomwise has appointed Mike Varney, Ph.D., as Lead Independent Director of the Board. Varney, a seasoned biotech leader, brings his experience from Genentech and Pfizer to support Atomwise's mission of revolutionizing small molecule drug discovery through AI.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Daily AI Brief.
Also, consider following us on social media:
Daily AI Brief
Daily report covering major AI developments and industry news, with both top stories and complete market updates
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Matt Clifford resigns as ARIA chair to join Anthropic
Voxel Appoints Three Executives to Lead Revenue and AI Operations
Nuritas Names Kees Kruythoff Board Chair
BioVid Launches Tumor Worlds for Oncology Market Intelligence
Workday Forms AI Research Team for Enterprise AI
Daily AI Brief: the AI news that matters, in your inbox.